Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 1
2016 3
2017 6
2018 7
2019 4
2020 9
2021 11
2022 9
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of Messenger RNA-1273 Against Severe Acute Respiratory Syndrome Coronavirus 2 Acquisition in Young Adults From March to December 2021.
Stephenson KE, Marcelin JR, Pettifor AE, Janes H, Brown E, Neradilek M, Yen C, Andriesen J, Grunenberg N, Espy N, Trahey M, Fischer RSB, DeSouza CA, Shisler JL, Connick E, Houpt ER, Chu HY, McCulloh RJ, Becker-Dreps S, Vielot NA, Kalbaugh CA, Cherabuddi K, Krueger KM, Rosenberg M, Greenberg RN, Joaquin A, Immergluck LC, Corey L, Kublin JG. Stephenson KE, et al. Among authors: cherabuddi k. Open Forum Infect Dis. 2023 Nov 2;10(11):ofad511. doi: 10.1093/ofid/ofad511. eCollection 2023 Nov. Open Forum Infect Dis. 2023. PMID: 38023544 Free PMC article.
Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor-Biased Ligand in Adults With COVID-19: Two Randomized Clinical Trials.
Self WH, Shotwell MS, Gibbs KW, de Wit M, Files DC, Harkins M, Hudock KM, Merck LH, Moskowitz A, Apodaca KD, Barksdale A, Safdar B, Javaheri A, Sturek JM, Schrager H, Iovine N, Tiffany B, Douglas IS, Levitt J, Busse LW, Ginde AA, Brown SM, Hager DN, Boyle K, Duggal A, Khan A, Lanspa M, Chen P, Puskarich M, Vonderhaar D, Venkateshaiah L, Gentile N, Rosenberg Y, Troendle J, Bistran-Hall AJ, DeClercq J, Lavieri R, Joly MM, Orr M, Pulley J, Rice TW, Schildcrout JS, Semler MW, Wang L, Bernard GR, Collins SP; ACTIV-4 Host Tissue Investigators. Self WH, et al. JAMA. 2023 Apr 11;329(14):1170-1182. doi: 10.1001/jama.2023.3546. JAMA. 2023. PMID: 37039791 Free PMC article.
Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization.
Wang TY, Wahed AS, Morris A, Kreuziger LB, Quigley JG, Lamas GA, Weissman AJ, Lopez-Sendon J, Knudson MM, Siegal DM, Kasthuri RS, Alexander AJ, Wahid L, Atassi B, Miller PJ, Lawson JW, Patel B, Krishnan JA, Shapiro NL, Martin DE, Kindzelski AL, Leifer ES, Joo J, Lyu L, Pennella A, Everett BM, Geraci MW, Anstrom KJ, Ortel TL; ACTIV-4C Study Group. Wang TY, et al. Ann Intern Med. 2023 Apr;176(4):515-523. doi: 10.7326/M22-3350. Epub 2023 Mar 21. Ann Intern Med. 2023. PMID: 36940444 Free PMC article. Clinical Trial.
Re-evaluation of cefepime or piperacillin/tazobactam to decrease use of carbapenems in ESBL-producing Enterobacterales urinary tract infections (REDUCE-UTI).
Branton AC, Vu CH, Venugopalan V, Santevecchi BA, Cherabuddi K, Ramphal R, Manohar T, Desear KE. Branton AC, et al. Among authors: cherabuddi k. JAC Antimicrob Resist. 2023 Mar 17;5(2):dlad021. doi: 10.1093/jacamr/dlad021. eCollection 2023 Apr. JAC Antimicrob Resist. 2023. PMID: 36936190 Free PMC article.
Digital cough monitoring - A potential predictive acoustic biomarker of clinical outcomes in hospitalized COVID-19 patients.
Altshuler E, Tannir B, Jolicoeur G, Rudd M, Saleem C, Cherabuddi K, Doré DH, Nagarsheth P, Brew J, Small PM, Glenn Morris J, Grandjean Lapierre S. Altshuler E, et al. Among authors: cherabuddi k. J Biomed Inform. 2023 Feb;138:104283. doi: 10.1016/j.jbi.2023.104283. Epub 2023 Jan 9. J Biomed Inform. 2023. PMID: 36632859 Free PMC article.
Use of therapeutic drug monitoring to characterize cefepime-related neurotoxicity.
Venugopalan V, Casaus D, Kainz L, Slaton CN, Hurst N, Bruzzone M, Hu C, Sword G, Cherabuddi K, Iovine N, Liu J, Scheetz MH, Rhodes N, Maranchick N, Peloquin CA, Klinker K, Alshaer MH. Venugopalan V, et al. Among authors: cherabuddi k. Pharmacotherapy. 2023 Jan;43(1):6-14. doi: 10.1002/phar.2744. Epub 2022 Dec 2. Pharmacotherapy. 2023. PMID: 36401796
Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial.
Chastre J, François B, Bourgeois M, Komnos A, Ferrer R, Rahav G, De Schryver N, Lepape A, Koksal I, Luyt CE, Sánchez-García M, Torres A, Eggimann P, Koulenti D, Holland TL, Ali O, Shoemaker K, Ren P, Sauser J, Ruzin A, Tabor DE, Akhgar A, Wu Y, Jiang Y, DiGiandomenico A, Colbert S, Vandamme D, Coenjaerts F, Malhotra-Kumar S, Timbermont L, Oliver A, Barraud O, Bellamy T, Bonten M, Goossens H, Reisner C, Esser MT, Jafri HS; COMBACTE-MAGNET EVADE Study Group. Chastre J, et al. Crit Care. 2022 Nov 15;26(1):355. doi: 10.1186/s13054-022-04204-9. Crit Care. 2022. PMID: 36380312 Free PMC article. Clinical Trial.
Re-evaluation of cefepime or piperacillin-tazobactam to decrease use of carbapenems in extended-spectrum beta-lactamase-producing Enterobacterales bloodstream infections (REDUCE-BSI).
Vu CH, Venugopalan V, Santevecchi BA, Voils SA, Ramphal R, Cherabuddi K, DeSear K. Vu CH, et al. Among authors: cherabuddi k. Antimicrob Steward Healthc Epidemiol. 2022 Mar 11;2(1):e39. doi: 10.1017/ash.2022.21. eCollection 2022. Antimicrob Steward Healthc Epidemiol. 2022. PMID: 36310806 Free PMC article.
52 results